Ambrx Biopharma Cayman, Inc.
DelistedCIK 1836056fmd_1GAT2PMX1137CHR17NT2JG7H35Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Jun 30, 2023, 9 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
| Total revenues | 10 | 14 | 7 | 7 |
| Research and development | 26 | 20 | 54 | 53 |
| Total operating expenses | 33 | 27 | 72 | 84 |
| Operating income | (22) | (13) | (64) | (76) |
| Interest expense | – | – | 0 | 1 |
| Interest and investment income | 0 | 0 | 0 | – |
| Other non-operating income (expense) | 0 | (5) | (4) | 0 |
| Income before taxes | (22) | (18) | (68) | (76) |
| Income tax expense | (0) | 0 | 0 | 2 |
| Net income from continuing operations | (22) | (18) | (68) | (78) |
| Net income | (20) | (17) | (68) | (78) |